NLRP3 炎症小体在急性冠脉综合征的研究进展

莹 付(承德医学院附属医院，中国)
卓妍 赵(承德医学院附属医院，中国)
爽 谢(承德医学院附属医院，中国)
傲雪 梅(承德医学院附属医院，中国)
英 张(承德医学院附属医院，中国)

摘要

急性冠脉综合征(acute coronary syndrome,ACS)是一类严重威胁人类健康的心血管疾病，其病理生理学机制涉及动脉粥样斑块破裂、动脉血栓形成及复杂的炎症反应。炎症一直被认为是动脉粥样硬化的关键因素。NLRP3炎症小体作为在NLRs家族中研究最深入、最成熟的成员之一，在多种炎症相关疾病中的作用备受关注。NLRP3炎症小体在冠状动脉性心脏病中参与了炎症和氧化应激，在心血管疾病的发病机制中起关键作用。因此，应用药物干扰NLRP3炎症小体等相关指标的激活，有效降低心血管动脉粥样硬化从而预防心肌细胞死亡，可能成为ACS的有效治疗策略。本文对与ACS相关的NLRP3炎症小体的最近研究进展进行总结，以便围绕该主题进行深入、全面的研究，为ACS的临床治疗提供参考。

关键词

NLRP3；炎症小体；急性冠脉综合征

参考

Bhatt DL, Lopes RD, Harrington RA. Diagnosis and Treatment of Acute Coronary Syndromes: A Review. JAMA. 2022 Feb 15;327(7):662-675.

刘明波,何新叶,杨晓红,等.《中国心血管健康与疾病报告2023》要点解读[J].中国心血管杂志,2024,29(04):305-324.

Liberale L, Montecucco F, Schwarz L, et al. Inflammation and cardiovascular diseases: lessons from seminal clinical trials. Cardiovasc Res. 2021 Jan 21;117(2):411-422.

Abbate A, Toldo S, Marchetti C, et al. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. Circ Res. 2020 Apr 24;126(9):1260-1280.

Ising C, Venegas C, Zhang S, et al. NLRP3 inflammasome activation drives tau pathology. Nature. 2019 Nov;575(7784):669-673.

Fu J, Wu H. Structural Mechanisms of NLRP3 Inflammasome Assembly and Activation. Annu Rev Immunol. 2023 Apr 26;41:301-316.

Takahashi M. NLRP3 inflammasome as a key driver of vascular disease. Cardiovasc Res. 2022;118(2):372-385.

Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-1131.

Theofilis P, Oikonomou E, Chasikidis C, et al. Inflammasomes in Atherosclerosis-From Pathophysiology to Treatment. Pharmaceuticals (Basel). 2023 Aug 28;16(9):1211.

Koushki K, Shahbaz SK, Mashayekhi K, et al. Anti-inflammatory Action of Statins in Cardiovascular Disease: the Role of Inflammasome and Toll-Like Receptor Pathways. Clin Rev Allergy Immunol. 2021 Apr;60(2):175-199.

Tall AR, Westerterp M. Inflammasomes, neutrophil extracellular traps, and cholesterol. J Lipid Res. 2019 Apr;60(4):721-727.

Rajamäki K, Lappalainen J, Oörni K, et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One. 2010 Jul 23;5(7):e11765.

Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010 Apr 29;464(7293):1357-61.

Afrasyab A, Qu P, Zhao Y, et al. Correlation of NLRP3 with severity and prognosis of coronary atherosclerosis in acute coronary syndrome patients. Heart Vessels. 2016 Aug;31(8):1218-29.

Wang L, Qu P, Zhao J, et al. NLRP3 and downstream cytokine expression elevated in the monocytes of patients with coronary artery disease. Arch Med Sci. 2014 Aug 29;10(4):791-800.

Zhang L, Jiang YH, Fan C, et al. MCC950 attenuates doxorubicin-induced myocardial injury in vivo and in vitro by inhibiting NLRP3-mediated pyroptosis. Biomed Pharmacother. 2021 Nov;143:112133.

Chen A, Chen Z, Zhou Y,et al. Rosuvastatin protects against coronary microembolization-induced cardiac injury via inhibiting NLRP3 inflammasome activation. Cell Death Dis. 2021 Jan 12;12(1):78.

Ridker PM, Bhatt DL, Pradhan AD, et al. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. Lancet. 2023 Apr 15;401(10384):1293-1301.

Toldo S, Mezzaroma E, Buckley LF, et al. Targeting the NLRP3 inflammasome in cardiovascular diseases. Pharmacol Ther. 2022 Aug;236:108053.

Yang M, Lv H, Liu Q, et al. Colchicine Alleviates Cholesterol Crystal-Induced Endothelial Cell Pyroptosis through Activating AMPK/SIRT1 Pathway. Oxid Med Cell Longev. 2020 Jul 15;2020:9173530.

Silvis MJM, Fiolet ATL, Opstal TSJ, et al. Colchicine reduces extracellular vesicle NLRP3 inflammasome protein levels in chronic coronary disease: A LoDoCo2 biomarker substudy. Atherosclerosis. 2021 Oct;334:93-100.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v8i2.24025